Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Neurology & Psychiatry
Filter     Order     Display # 
Date Item Title
24 Jan 2008 Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
23 Jan 2008 DIREVO to collaborate with MedImmune on therapeutic protease for the treatment of CNS diseases
23 Jan 2008 NovaDel's New Drug Application for ZolpiMist(TM) Oral Spray to Treat Insomnia Accepted for Filing by the U.S. Food and Drug Administration
22 Jan 2008 Northstar Neuroscience Announces Primary Endpoint Results of EVEREST Clinical Trial
22 Jan 2008 Synosia announces encouraging results of proof-of-concept clinical trial for epilepsy drug rufinamide as a treatment for mood disorders
18 Jan 2008 StemCells, Inc. Provides Batten's Clinical Trial Update
18 Jan 2008 Trophos reaches mid-point of Phase II Clinical Trial of TRO19622 in painful diabetic neuropathy
17 Jan 2008 YM BioSciences Provides Update on AeroLEF(TM) Clinical Development Program
17 Jan 2008 Serenex and CHDI Form Agreement to Evaluate Proprietary Small Molecule Hsp90 Inhibitors as a Potential Treatment for Huntington's Disease
17 Jan 2008 FDA Approves ZymoGenetics' RECOTHROM(TM) Thrombin, topical
16 Jan 2008 Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate Its Diclofenac Patch for Mild to Moderate Pain
16 Jan 2008 CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
16 Jan 2008 Keppra XR(TM) Extended- Release Tablets Filed with the FDA
16 Jan 2008 EPIX Pharmaceuticals Announces Updated Results from Phase 2a Clinical Trial of PRX-03140 in Alzheimer's Disease
15 Jan 2008 GlaxoSmithKline and XenoPort report positive top-line results of second phase 3 restless legs syndrome trial for XP13512/GSK1838262
15 Jan 2008 POZEN Submits Human Lymphocyte Study for Treximet(TM) (Formerly Known as Trexima(TM))
15 Jan 2008 Preclinical studies show Allon's drug AL-108 impacts Alzheimer's pathology and behaviour
11 Jan 2008 Progenics and Wyeth Announce NDA Review Period for Subcutaneous Methylnaltrexone Extended by Three Months
11 Jan 2008 Amarin to Commence Phase II Trial With amr101 in Age Associated Memory Impairment
11 Jan 2008 Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
10 Jan 2008 Allon trial studies pharmacokinetics of AL-108 & AL-208
09 Jan 2008 Somaxon Pharmaceuticals Announces Completion of 26-WeekTransegenic Mouse Carcinogenicity Study of SILENOR(TM)
09 Jan 2008 Amarin Announces Successful Outcome of Nasal Lorazepam Study
08 Jan 2008 Sangamo BioSciences Initiates Phase 2 Clinical Trial of ZFP Therapeutic in Stem Cell Mobilization
07 Jan 2008 Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate
07 Jan 2008 Phase I Safety and Tolerability Study with EVT 302 Successfully Completed
07 Jan 2008 Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
07 Jan 2008 Pipex Pharmaceuticals Initiates Phase II Clinical Trial of Anti-Copper COPREXA for Alzheimer's Disease
04 Jan 2008 Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
04 Jan 2008 ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ischemic Stroke
03 Jan 2008 Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia
03 Jan 2008 Addex Announces ADX10059 Phase IIa Acute Anxiety Data
03 Jan 2008 Update on pipeline - new pharmaceutical candidate Lu AA37096 enters Lundbeck's development pipeline
03 Jan 2008 AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
03 Jan 2008 FDA Approves Additional Dosage Strengths of Shire’s ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
02 Jan 2008 AstraZeneca Submits sNDAs for Seroquel XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
02 Jan 2008 Nalmefene United Kingdom and Ireland rights acquired by Lundbeck
02 Jan 2008 Sepracor Inc. and Bial Announce Exclusive Licensing Agreement for Development and Commercialization of Anti-Epileptic Compound in United States and Canada
02 Jan 2008 Prana Announces Completion of Phase IIa Trial of PBT2 in Alzheimer's Disease Patients
31 Dec 2007 Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
28 Dec 2007 Adolor Announces Investigational New Drug Application for Novel Delta Agonist ADL5747
27 Dec 2007 Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
27 Dec 2007 Leiden University Medical Center and Prosensa B.V. Announce New England Journal of Medicine Publication of First Successful Clinical Study with RNA-based Therapeutic PRO051 in Duchenne Muscular Dystrophy
26 Dec 2007 Noven announces FDA tentative approval of Stavzor (TM) Valproic acid delayed release capsules
22 Dec 2007 Elan and Wyeth Dose First Patient in North America in Phase 3 Program for Bapineuzumab (AAB-001) in Alzheimer's Disease
21 Dec 2007 Lundbeck expands agreement with PAION for desmoteplase
21 Dec 2007 Elan and Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
21 Dec 2007 FDA issues approvable letter for LUVOX (R) CR extended-release capsules for the treatment of social anxiety disorder and obsessive compulsive disorder
20 Dec 2007 CytRx Initiates Phase IIb Efficacy Clinical Trial with Arimoclomol for Treatment of ALS
20 Dec 2007 Exonhit gets regulatory approval to initiate a Phase 2 clinical trial for EHT 0202 in Alzheimer's Disease
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 401 - 450 of 1619

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics